◈ Nootpedia
Compact view
Research pass: thorough Pharmaceutical · Oral SKIP-FOR-NOW HIGH

Lisuride

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict SKIP-FOR-NOW HIGH

Direct dopamine receptor agonism carries class-warning impulse-control-disorder (ICD) risk — pathological gambling, hypersexuality, compulsive shopping/eating — at population rates of 2.8-8% in PD patients, and the receptor-level mechanism does not care whether the user is 70 with PD or 20 with a developing prefrontal cortex. Lisuride is the cleanest ergoline on the cardiac axis (5-HT2B antagonism actively prevents valvulopathy that killed pergolide and benched cabergoline) but cleanness vs. its ergoline siblings is irrelevant when the question is whether a 20-year-old MMA athlete should be a chronic direct DA agonist user. Verdict would change to OPTIONAL-CONSIDER if Dylan develops a prescriber-managed Parkinson's-adjunct context (he won't), or to WATCH-LIST if a credible PK-tuned microdose protocol with prospective ICD monitoring emerges in the biohacker literature (none exists — current biohacker use is anecdotal Ray-Peat-forum off-label and mostly for prolactin lowering, which Dylan does not need).

Research pass: thorough
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    SKIP-FOR-NOW

    Direct DA agonism + ICD class risk + brain-development context at 20 + cleaner alternatives (selegiline, bromantane, BPAP) cover the same dopaminergic goals upstream, without postsynaptic forcing. The 5-HT2B-antagonist cardiac safety is real but irrelevant when the question is whether a 20-year-old should be a chronic direct DA agonist user at all.

  • 30-50, executive maintenance
    SKIP

    unless prescriber-managed for hyperprolactinemia or specific indication. ICD risk applies fully.

  • 50+, mild cognitive decline
    CONSIDER

    under neurology supervision if Parkinson's-spectrum or hyperprolactinemia indicated; otherwise SKIP.

  • Anxiety-prone
    CAUTION

    5-HT1A agonism can be anxiolytic, but DA agonism + α-blockade can produce activation/jitteriness/orthostatic anxiety. Net effect unpredictable.

  • High athletic load, tested status
    SKIP

    Orthostasis + nausea are bad for training; lisuride is not WADA-banned but no athletic upside justifies the side-effect profile.

  • Sleep-disordered
    SKIP

    Some users report better circadian timing (5-HT2C effect); many report sleep disturbance and vivid dreaming.

  • Recovery-focused (post-injury, post-illness)
    SKIP

    No recovery-specific benefit.

  • Strength/anabolic-focused
    SKIP

    Mild prolactin-lowering effect is not a meaningful anabolic lever on top of normal endocrine function; more directly anabolic interventions exist; HPG-axis interactions via prolactin axis are minor and not worth dopamine-agonist class risk.

▸ Subjective experience (deep)

At biohacker doses (25-100 mcg sublingual or topical, off-label):

  • Onset: 30-60 min sublingual; faster topical
  • Peak: 1-2 hours
  • Duration of acute effect: 3-6 hours, but receptor-level effects (especially 5-HT2B blockade) outlast plasma exposure substantially
  • Characteristic positive reports: Subtle dopaminergic lift — described as "a quieter, more focused interest in things." Mild euphoria for some. A few users report a faint dissociative or "mild psychedelic" texture at the upper end (75-100 mcg), consistent with the 5-HT2A partial agonism. Some users report improved morning waking and circadian regularity (5-HT2C agonism plausibly contributory).
  • Characteristic negative reports: Nausea (very common, sometimes severe — class effect of DA agonists at start), orthostatic dizziness (α-adrenergic antagonism), sleep disturbance / vivid dreaming if dosed too late, sedation/sleepiness for some users, "weakness" for 1-2 hours post-dose for some, headache. At PD doses (0.5-2+ mg/day) the psychiatric profile (hallucinations, confusion) dominates.
  • High variability: The interpersonal variability in oral bioavailability (poor + highly individual) plus the broad receptor coverage means subjective response varies more than for most psychoactives. Some users feel substantial effect at 25 mcg; others feel nothing at 100 mcg.

For Dylan specifically the predicted experience profile is unclear (no titrated data from people with his receptor genotype + DA tone) and the asymmetry of the bet is bad — best case a subtle lift indistinguishable from selegiline + caffeine + bromantane; worst case nausea/orthostasis + slow accumulation of impulse-control dysregulation he cannot self-detect.

▸ Tolerance + cycling deep dive
  • Tolerance to therapeutic DA effect: Limited / slow in clinical PD use (durable efficacy over years).
  • Tolerance to nausea: Develops within weeks (this is desirable).
  • Tolerance to subjective "lift": Highly variable; some biohackers report tachyphylaxis after weeks of daily use, others report sustained effect.
  • Receptor downregulation: Less concerning than for high-Emax DA releasers (amphetamines) because the partial-agonist profile at D2/D3/D4 may blunt postsynaptic downregulation, but chronic exogenous receptor stimulation is not a free lunch — endogenous DA tone may compensate downward over months.
  • Cycling: No standardized cycle exists for nootropic use. Some forum protocols dose 1-2x weekly relying on long receptor occupancy. No data on whether this is genuinely tolerance-sparing or merely under-dosed.
  • Reset protocol: Wash out is fast (half-life ~2h), but receptor effects persist; meaningful "reset" likely takes weeks rather than days for chronic users.
▸ Stacking deep dive

Synergistic with (in the "do not stack" sense — listed because users will ask)

  • Levodopa: classic clinical adjunct combination (Parkinson's only — not a biohacker stack)
  • Other DA agonists (pramipexole, ropinirole, rotigotine): redundant + cumulative ICD risk; do not combine

Avoid stacking with

  • Other direct DA agonists (pramipexole, ropinirole, bromocriptine, cabergoline, pergolide, apomorphine): redundant DA receptor occupancy + cumulative ICD risk
  • Selegiline / rasagiline / safinamide (MAO-B inhibitors): theoretically additive on DA tone; in PD clinical practice this combination is used but with care — for biohacker stacking purposes, layering a direct DA agonist on top of MAO-B inhibition is exactly the receptor-level overstimulation Dylan should avoid
  • Bromocriptine / cabergoline / pergolide: redundant ergoline + cumulative cardiac concern (less relevant for lisuride itself due to its 5-HT2B antagonism, but you would be loading the others' agonism on top of lisuride's antagonism — incoherent)
  • Strong CYP3A4 inhibitors (itraconazole, ketoconazole, ritonavir, clarithromycin, grapefruit at extreme amounts): elevated lisuride exposure
  • 5-HT1A agonists at high dose (buspirone): may amplify the 5-HT1A axis in unpredictable ways
  • Antipsychotics (D2 antagonists): mutual antagonism; do not combine
  • MAOIs (non-selective): hypertensive crisis risk via amplified monoamine effects + ergoline scaffold concern

Neutral / safe co-administration (for the people who will use it anyway, despite Dylan not being one of them)

  • L-theanine: complementary calming
  • Magnesium: complementary; no mechanistic conflict
  • Omega-3 / DHA: no interaction
  • Caffeine: pharmacodynamic stack possible (DA + adenosine), but layered nausea / orthostasis risk
▸ Drug interactions deep dive
  • CYP3A4: Lisuride is a CYP3A4 substrate. Strong CYP3A4 inhibitors (azole antifungals, macrolide antibiotics, ritonavir, grapefruit at high intake) elevate exposure; strong inducers (rifampin, carbamazepine, St. John's wort) reduce exposure.
  • Antihypertensives: Additive hypotensive / orthostatic effect.
  • Dopamine antagonists (haloperidol, risperidone, olanzapine, metoclopramide, prochlorperazine): mutual antagonism. Antiemetics should be 5-HT3 (ondansetron) or peripheral D2 (domperidone, where available) rather than central D2 antagonists.
  • Serotonergic agents (SSRIs, SNRIs, MAOIs, triptans): theoretical serotonergic concern given lisuride's 5-HT1A/1B/1D agonism; clinical reports are limited but the combination warrants caution.
  • Alcohol: additive sedation, additive hypotension.
  • Hormonal contraceptives: No major documented interaction.
▸ Pharmacogenomics
  • CYP3A4/CYP3A5 polymorphisms: plausibly relevant given hepatic metabolism, but lisuride-specific PGx data is thin.
  • DRD2 / DRD3 polymorphisms: Common DRD2 Taq1A and DRD3 Ser9Gly variants modulate response to all DA agonists; lisuride-specific data is sparse but the broader DA-agonist literature applies.
  • No 23andMe-actionable lisuride-specific guidance exists as of 2026-05.
▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
Research chemical (US) IdeaLabs (idealabs.ecwid.com) — liquid lisuride product ~$30-50 / vial Medium-high (established Ray-Peat-forum vendor; sells as lab/R&D, not for human use) Most common biohacker source. Liquid format requires refrigeration ≤20°C. Topical or sublingual dosing per forum convention. No COA published per batch by default.
Rx (EU) — Dopergin / Cuvalit / Revanil EU pharmacy on Rx Variable High Requires EU prescriber and physical Rx; not realistic for a US biohacker.
Rx (Japan, some LATAM) Local pharmacy on Rx Variable High Same constraint.
Indian online pharmacy Limited availability Variable Low-medium Lisuride is not a major Indian generic; harder to source than modafinil, bromantane, etc.
Compounding pharmacy (US) Specialized compounders, w/ prescriber willing to write off-label High Medium Theoretically possible; not common; requires Rx for unapproved drug → very few US prescribers will write.

Sourcing reality for Dylan: The realistic path is research-chemical IdeaLabs liquid. This is the same vendor type the V5 stack already uses for Russian peptides etc., so trust isn't the bottleneck — but for a compound where the failure mode is impulse-control behavioral dysregulation (subtle, slow, hard to self-monitor), research-chem sourcing layered on a direct DA agonist class is a stack-up of risk for no clear gain.

▸ Biomarkers to track (deep)
  • Baseline: prolactin, full hormone panel, resting + standing BP, HR, echocardiogram (regulatory carryover from ergoline class — even though lisuride-specific risk is low), liver panel (ALT/AST), psychiatric self-report baseline (impulsivity, mood, sleep)
  • During use: monthly resting + orthostatic BP × 3 months then quarterly; prolactin at month 1 and month 3; quarterly impulsivity self-report + partner-report (the more important measurement); annual echo for chronic PD-dose users; liver panel quarterly first year then annually
  • Post-cycle: prolactin rebound check; mood/impulsivity normalization tracking
▸ Controversies / open debates Live debate
  • "Lisuride is the cleanest ergoline" — true. The 5-HT2B antagonism is real, the cardiac pharmacovigilance signal across ~360,000 patient-years is real, the mechanism prediction was vindicated. This is one of the more impressive pharmacology-to-pharmacovigilance success stories.
  • "Cleaner cardiac profile = should be preferred over pergolide/cabergoline" — yes, in PD context with prescriber. Off-market US status is more about commercial failure (poor oral bioavailability + crowded-market dynamics in the 1980s-90s) than about safety; lisuride is in some ways the most safety-justified ergoline.
  • "Lisuride has cognitive / nootropic benefit" — mostly anecdotal. Forum reports are mixed; no controlled cognitive data in healthy adults exists. The dopaminergic-lift claim is plausible mechanistically but indistinguishable from what selegiline + caffeine deliver more cleanly.
  • "Lisuride is a non-psychedelic 5-HT2A agonist and could probe serotonergic biology safely" — true in research, irrelevant to a biohacker. The 2023-2025 work (Roth, Olson, Sharp) using lisuride as the canonical non-psychedelic 5-HT2A control is real and useful. None of this implies clinical or nootropic benefit for a healthy user.
  • "5-HT2B antagonism is anti-fibrotic and cardioprotective — should we all be on lisuride for longevity?" — no. The forum-bioenergetic argument extrapolates anti-fibrotic mechanism into general longevity benefit. There is zero RCT support for this in healthy users, and the dopaminergic side of the molecule carries risks that any putative anti-fibrotic benefit cannot offset for a 20-year-old.
  • ICD risk: does the lisuride-specific zero-cases-in-94 finding mean it is safer than other DA agonists? Probably no — it likely reflects denominator effects (much lower lisuride use vs. pramipexole/ropinirole). The class warning language is in the SmPC for a reason.
▸ Verdict change log
  • 2026-05-05 — Initial verdict: SKIP-FOR-NOW (HIGH confidence). Direct dopamine agonism with class-level ICD risk; brain-development concerns at 20; cleaner alternatives (selegiline, bromantane, BPAP) achieve comparable dopaminergic goals upstream. 5-HT2B-antagonist cardiac safety is genuinely elegant but irrelevant to the question of whether a 20-year-old should be a chronic direct DA agonist user. Verdict would change to OPTIONAL-CONSIDER under prescriber-managed Parkinson's-adjunct context (not Dylan's situation), or to WATCH-LIST if a credible PK-tuned microdose protocol with prospective ICD monitoring landed in the biohacker literature (none exists today).
▸ Open questions / gaps Open
  • No controlled human data on subclinical-dose nootropic use. All "biohacker microdose" claims are forum anecdote.
  • No PGx-specific guidance. CYP3A4 and DRD2/DRD3 modulation is theoretically relevant; no published lisuride-specific PGx work to act on.
  • Chronic-use ICD time-course at sub-therapeutic doses is uncharacterized. The clinical ICD literature is at PD doses (0.5+ mg/day); whether 25-100 mcg microdose protocols carry meaningfully reduced ICD risk is unknown.
  • Long-tailed receptor occupancy (5-HT2B blockade outlasting plasma exposure) is documented but the practical implication for intermittent dosing is under-studied.
  • What would change the verdict for Dylan specifically: (1) prescriber-managed indication appearing (won't happen at 20, healthy); (2) credible biohacker protocol with prospective ICD self-monitoring + bloodwork pipeline; (3) a PD diagnosis decades from now; (4) compelling head-to-head vs. selegiline/bromantane for cognitive endpoint (does not exist).
▸ Sources (full, with our context)
Back to compact view